ReviewJournal of translational medicine2009
Immunological considerations of modern animal models of malignant primary brain tumors.
Review in Journal of translational medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 29 citations in OpenAlex.
- Speeding up Glioblastoma Cancer Research: Highlighting the Zebrafish Xenograft Model.International journal of molecular sciences · 2024Review
- Article
- Targeting Myeloid Cells in Combination Treatments for Glioma and Other Tumors.Frontiers in immunology · 2019Review
- Optical Barcoding for Single-Clone Tracking to Study Tumor Heterogeneity.Molecular therapy : the journal of the American Society of Gene Therapy · 2017Article
- Bioluminescence Imaging of an Immunocompetent Animal Model for Glioblastoma.Journal of visualized experiments : JoVE · 2016Article
- Histamine deficiency promotes accumulation of immunosuppressive immature myeloid cells and growth of murine gliomas.Oncoimmunology · 2015Article
- Stable luciferase expression does not alter immunologic or in vivo growth properties of GL261 murine glioma cells.Journal of translational medicine · 2014Article
- Immunocompetent murine models for the study of glioblastoma immunotherapy.Journal of translational medicine · 2014Review
- Depleting tumor-specific Tregs at a single site eradicates disseminated tumors.The Journal of clinical investigation · 2013Article
- Stabilin-1 expression in tumor associated macrophages.Brain research · 2012Article
- Antitumor activity of a polypyridyl chelating ligand: in vitro and in vivo inhibition of glioma.ASN neuroArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent advances in animal models of glioma have facilitated a better understanding of biological mechanisms underlying gliomagenesis and glioma progression. The limitations of existing therapy, including surgery, chemotherapy, and radiotherapy, have prompted numerous investigators to search for new therapeutic approaches to improve quantity and quality of survival from these aggressive lesions. One of these approaches involves triggering a tumor specific immune response. However, a difficulty in this approach is the the scarcity of animal models of primary CNS neoplasms which faithfully recapitulate these tumors and their interaction with the host's immune system. In this article, we review the existing methods utilized to date for modeling gliomas in rodents, with a focus on the known as well as potential immunological aspects of these models. As this review demonstrates, many of these models have inherent immune system limitations, and the impact of these limitations on studies on the influence of pre-clinical therapeutics testing warrants further attention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.